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EPTC, or S-ethyl-N-N-dipropylthiocarba-
mate, is a preemergence and early postemer-
gence thiocarbamate herbicide used to
manage the growth of annual weeds includ-
ing broadleaves, grasses, and sedges. EPTC is
widely applied with the safener dichlormid
(2,2-dichloro-N,N-di-2-propenylacetamide)
(Abu-Qare and Duncan 2002) to reduce
crop-speciﬁc phytotoxicity. EPTC is used in
every region of the United States in the agri-
cultural production of a wide variety of food
crops including corn, potatoes, dry beans,
and alfalfa. In 1999, EPTC was the 19th
most commonly used pesticide active ingredi-
ent in U.S. agriculture [U.S. Environmental
Protection Agency (EPA) 2002]. The U.S.
EPA (2006) estimates that the total amount
of EPTC used has decreased from an average
of 21 million pounds in 1987 to 9 million
pounds in 1999. States reporting the highest
annual use of EPTC between 1995 and 1997
were in the northern Great Plains; Iowa,
Nebraska, Minnesota, and South Dakota
(U.S. Geological Survey 2004). EPTC is
available as an emusiﬁable concentrate and in
a granular formulation. Depending on the
formulation, EPTC can be applied by disk-
ing, soil injection, and spray. EPTC has a
relatively short half-life in soil ranging from
2 to 18 days, depending on microbial con-
ditions. Degradation of EPTC can occur
through chemical, biologic, and photo-
chemical processes (Abu-Qare and Duncan
2002; Nagy et al. 1995). 
Because of its volatile nature and short soil
half-life, EPTC is not persistent and does not
bioaccumulate up the food chain. Because
EPTC does not remain in the environment,
the primary route for human exposure is likely
nondietary, through dermal contact and
inhalation (U.S. EPA 1999). The U.S. EPA
has classiﬁed EPTC as a general use pesticide
that is moderately toxic (Toxicity Category III)
via oral and dermal routes (U.S. EPA 1999).
In subchronic and chronic studies performed
in both rats and dogs, EPTC exposure resulted
in cardiomyopathy and neurotoxicity in the
central and peripheral nervous systems (U.S.
EPA 2006). Toxicity occurs through the by-
products of EPTC metabolism, which inhibit
the enzymatic activities of aldehyde dehydro-
genase and cholinesterase (Smulders et al.
2003, 2004; Staub et al. 1995; Zimmerman
et al. 2004). 
Using the 1999 Guidelines for Carcinogen
Risk Assessment and the Ames mutagenicity test
(U.S. EPA 1999), the U.S. EPA reports that
EPTC is most likely not a carcinogen. This
review was based on long-term studies in small
rodents and short-term mutagenicity studies
(Dickie 1987; Tisdel 1986). Similar work
using human peripheral lymphocytes also indi-
cated that EPTC and other thiocarbamates,
when applied directly to cells, do not induce
DNA damage (Calderon-Segura et al. 1999,
2007). However, EPTC exerts its herbicidal
effects after metabolic transformation into its
sulfoxide and sulfone derivatives produced by
oxidation reactions (Hubbell and Casida
1977). Recent animal studies found that
EPTC sulfoxide can form DNA adducts in rat
hepatocytes (Zimmerman et al. 2004) and
induces DNA damage in human lymphocytes
(Calderon-Segura et al. 2007). In mammals,
the same reactive electrophilic intermediates
are formed through sulfoxidation and oxida-
tion reactions as part of the normal detoxiﬁca-
tion pathways (Chen and Casida 1978;
Hubbell and Casida 1977). How efficiently
humans metabolize and excrete EPTC and its
metabolites remains unclear.
The epidemiologic data on EPTC expo-
sure and cancer risk are limited. An earlier
study using data unrelated to the Agricultural
Health Study (AHS) reported a modest
increased risk of non-Hodgkin lymphoma
among farmers who applied carbamate pesti-
cides when compared with nonfarmers
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BACKGROUND: The Agricultural Health Study (AHS) is a prospective cohort study of licensed
pesticide applicators from Iowa and North Carolina enrolled between 1993 and 1997. EPTC
(S-ethyl-N,N-dipropylthiocarbamate) is a thiocarbamate herbicide used in every region of the United
States. The U.S. Environmental Protection Agency reports that EPTC is most likely not a human car-
cinogen; however, the previous epidemiologic data on EPTC exposure and cancer risk were limited. 
OBJECTIVES: The purpose of this study was to examine cancer incidence and EPTC use in 48,378
male pesticide applicators enrolled in the AHS. 
METHODS: We estimated the rate ratio (RR) and 95% conﬁdence intervals (CIs) for all cancers and
selected cancer sites using Poisson regression. We assessed EPTC exposure using two quantitative
metrics: lifetime exposure days and intensity-weighted lifetime exposure days, a measure that
accounts for application factors that modify personal exposure likelihood. 
RESULTS: Among the 9,878 applicators exposed to EPTC, 470 incident cancer cases were diagnosed
during the follow-up period ending December 2004 compared with the 1,824 cases among individ-
uals reporting no use. Although EPTC was associated with colon cancer in the highest tertile of
both lifetime exposure days and intensity-weighted lifetime days (RR = 2.09; 95% CI, 1.26–3.47
and RR = 2.05; 95% CI, 1.34–3.14, respectively) and the trend test was < 0.01 for both, the pat-
tern of RR was not monotonic with increasing use. There was a suggestion of an association with
leukemia. No other associations were observed.
CONCLUSION: In this analysis, EPTC use appeared to be associated with colon cancer and leukemia.
However, given the relatively small number of cases in the highest exposure tertile, results should
be interpreted with caution, and further investigations are needed. 
KEY WORDS: agriculture, cancer, EPTC, herbicide, neoplasms, occupational exposure, pesticides,
thiocarbamates. Environ Health Perspect 116:1541–1546 (2008). doi:10.1289/ehp.11371 available
via http://dx.doi.org/ [Online 26 June 2008](Zheng et al. 2001). Earlier analyses within
the AHS report no association between ever
using EPTC and prostate (Alavanja et al.
2003), colon, or rectal cancer (Lee et al.
2007). Here, we investigate potential associa-
tions between a number of cancer sites and
self-reported use of EPTC among pesticide
applicators enrolled in the AHS. 
Methods
Cohort enrollment and follow-up. The AHS is
a prospective cohort study of 57,311 licensed
pesticide applicators and their spouses (n =
32,347) in Iowa and North Carolina
(Alavanja et al. 1996). Only private applica-
tors (primarily farmers) were recruited from
North Carolina; in Iowa, both commercial
and private applicators were enrolled.
Commercial applicators include individuals
employed by companies that regularly use pes-
ticides. All applicators were recruited between
December 1993 and December 1997 from
certification sessions that are required to use
U.S. EPA–designated “Restricted Use
Pesticides.” Participants completed an enroll-
ment questionnaire while attending the certiﬁ-
cation session. Incident cancer cases were
identiﬁed by matching cohort information to
cancer registry files in both Iowa and North
Carolina through December 2004 (AHS data
release version P1REL0612; unpublished
data). Annually, members of the cohort were
matched to the National Death Index
(National Center for Health Statistics,
Hyattsville, MD) to determine vital status.
Current address records were compared with
motor vehicle registration records, pesticides
license registries from each state agricultural
department, and address records from the
Internal Revenue Service to verify that partici-
pants continued to reside in Iowa or North
Carolina. Individuals were censored at the
time of death or relocation out of the partici-
pating states. Informed consent was obtained
from all participants, and the protocol was
approved by all appropriate institutional
review boards. We excluded female applicators
(n = 1,563) for this analysis because only 82
reported ever using EPTC, among whom only
two cases of cancer were observed. 
Exposure assessment. Exposure to EPTC
and other items was assessed through self-
report. Questionnaires are available online at
http://www.aghealth.org (National Institutes
of Health 2004). Detailed information on the
use of 22 speciﬁc pesticides, including EPTC,
was collected in the enrollment questionnaire,
and on ever/never use for an additional 28 spe-
ciﬁc pesticides. In addition, information was
obtained on pesticide mixing and application
methods, types of equipment repair routinely
performed, and use of personal protective
equipment. Participants also provided informa-
tion on lifestyle and other factors associated
with an increased risk of developing specific
cancer, including smoking history, alcohol use,
a first-degree relative diagnosed with cancer,
diet, and basic demographic characteristics. 
We evaluated EPTC exposure using two
metrics: lifetime exposure days and intensity-
weighted lifetime exposure days. Lifetime
exposure days were calculated as the product
of the years an individual mixed or applied
EPTC and the number of days in an average
year that EPTC was used. The intensity-
weighted score was calculated using a pub-
lished algorithm that accounts for many
factors that may inﬂuence pesticide exposure
(Dosemeci et al. 2002), including the effect of
modifying factors such as how often an appli-
cator personally mixed or prepared herbicides,
the type of application method used, whether
an applicator personally repaired pesticide
application equipment, and the type of per-
sonal protective equipment used. The precise
algorithm is as follows: intensity level = [(mix-
ing status + application method + equipment
repair status) × personal protective equipment
use]. The intensity score was multiplied by the
EPTC lifetime exposure days to obtain a ﬁnal
EPTC intensity-weighted exposure days value. 
Data analysis. Only male pesticide applica-
tors who completed the enrollment question-
naire were included in this analysis. Those with
prevalent cancer were excluded (n = 1,062), as
were pesticide applicators who did not provide
information on age (n = 1) or EPTC use (n =
6,307), restricting the initial analysis to 48,378
licensed pesticide applicators. An additional
50 participants were excluded from the analysis
using the intensity-weighted lifetime exposure
days because of incomplete data collection on
factors related to the algorithm. A sensitivity
analysis including these exclusions in the refer-
ent group was performed using both exposure
metrics. And Poisson regression analysis was
performed using the STATA statistical soft-
ware program (STATA version 9.0; StataCorp,
College Station, TX). Based on previous pesti-
cide studies, the first 10 factors listed in
Table 1 were put into the all-cancer regression
model individually to determine signiﬁcance
(p = < 0.05). We then used forward selection
to add significant variables to the regression
model. Three of the 10 variables evaluated
were rejected based on the above criteria. All
Poisson regression models were adjusted for
age as a categorical variable, race, smoking sta-
tus, alcohol consumption, state of residence,
family history of cancer (not including nonma-
lignant skin cancer), applicator type (commer-
cial/private), and lifetime days of all pesticide
use. Lifetime days of all pesticide use was
analyzed as both a categorical and continuous
variable. Because there were no signiﬁcant dif-
ferences between the two variables, we chose to
analyze lifetime days of all pesticide use as a
continuous variable. Additional modeling was
done to adjust for body mass index as a cate-
gorical variable for all cancer and colon cancer.
In cancer-speciﬁc analyses, we considered
27 different cancer sites [ICD-O2; International
Classification of Diseases for Oncology, Second
Revision (World Health Organization 1990)].
Except for leukemia and rectal cancer, only can-
cer sites with at least 20 cases among individuals
exposed to EPTC are listed in this report.
Those speciﬁc sites include combined category
of blood (including leukemia, non-Hodgkin
lymphoma, Hodgkin lymphoma, multiple
myeloma, and other cancers of the blood with
no known origin), non-Hodgkin lymphoma, as
well as bladder, colon, lung, and prostate can-
cers. Leukemia (n = 18 among those reporting
EPTC use) was included based on reports sug-
gesting a potential association between herbi-
cide use and an increase in leukemia risk and
chromosomal damage (Georgian et al. 1983;
Lee et al. 2004). Rectal cancer (n = 14 among
those reporting EPTC use) was analyzed based
on its anatomic proximity to the colon. 
Lifetime exposure days and intensity-
weighted lifetime exposure days were catego-
rized into tertiles based on the distribution of
exposure among all cancer cases. Both expo-
sure metrics were analyzed using two different
referent groups: no EPTC use and the lowest
tertile of EPTC use. It has been postulated
that pesticide users in the highest exposure
tertile may be more similar to applicators in
the lowest exposure group than they are to
never users (Rusiecki et al. 2004). Therefore,
we used the low-exposure group as a second
reference group to address potential unknown
confounding between the groups. We per-
formed a test for linear trend for both expo-
sure metrics by using the median for each
exposure category as the quantitative score.
All statistical tests were two sided. 
Results
Selected characteristics of the study population
are displayed in Table 1 according to lifetime
exposure days to EPTC. The low-exposure
group refers to participants in the lowest tertile
(< 10 lifetime exposure days), and the high-
exposure group is a combination of the top
two tertiles (≥ 10 lifetime exposure days).
Applicators were primarily white, with > 40%
attaining at least a high school diploma.
Regardless of exposure, approximately 50% of
participants were never smokers, and most
reported some alcohol use over the preceding
12 months. In general, the three exposure
groups (no exposure, low, and high) were sim-
ilar with respect to most demographic charac-
teristics, except for the predominance of
EPTC use by farmers in Iowa. 
EPTC exposure was initially divided into
no exposure (never users) and exposed (ever
users). For all cancer sites combined, 470 can-
cer diagnoses were made through December
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EPTC. In contrast, 1,824 cancers were diag-
nosed within that same time among those
with no exposure (n = 38,500). The mean
(± SD) age of cancer incidence in the study
population was 58 ± 10.3 years with a range
of 23–87 years. A small increase in risk for all
cancers was observed [rate ratio (RR) 1.14;
95% confidence interval (CI), 1.02–1.27].
No speciﬁc cancer was observed to be statisti-
cally associated with individuals ever exposed
to EPTC versus those never exposed, but the
risks for both colon cancer (RR = 1.35; 95%
CI, 0.93–1.97) and leukemia (RR = 1.31;
95% CI, 0.75–2.28) were elevated. The risk
for rectal cancer was not significant (RR =
0.80; 95% CI, 0.44–1.42). 
Table 2 summarizes our analysis investigat-
ing the association between cancer incidence
and EPTC lifetime exposure days (left panel).
We observed an increase in risk when compar-
ing the highest level of exposure for all cancer
(RR = 1.28; 95% CI, 1.09–1.50), colon cancer
(RR = 2.09; 95% CI, 1.26–3.47), and leukemia
(RR = 2.36; 95% CI, 1.16–4.84) with subjects
with no exposure. We also observed a signiﬁ-
cant increasing linear trend for the incidence of
these cancers (p-trend for all cancer < 0.01,
p-trend for colon cancer < 0.01, p-trend for
leukemia = 0.02). When the lowest exposure
tertile was used as the referent, we observed a
slight attenuation of the point estimate for all
cancer (RR = 1.13; 95% CI, 0.92–1.39,
p-trend = 0.05) and an increase for both colon
cancer (RR = 2.76; 95% CI, 1.27–6.00,
p-trend = 0.03) and leukemia (RR = 2.91; 95%
CI, 0.97–8.72, p-trend = 0.04). 
We also analyzed EPTC exposure by ter-
tiles of intensity-weighted lifetime exposure
days. The increased risk associated with EPTC
lifetime exposure days and colon cancer
remained constant when we used the intensity-
weighted lifetime exposure days metric (Table
2, right panel). The associated risks for all can-
cer and leukemia were slightly attenuated using
the intensity-weighted lifetime days exposure
scale. When comparing the highest tertile of
EPTC exposure with those with no exposure,
we found increased risks for all cancer
(RR = 1.16; 95% CI, 1.01–1.35), colon cancer
(RR = 2.05; 95% CI, 1.34–3.14), and leukemia
(RR = 1.87; 95% CI, 0.97–3.59). When the
lowest tertile of exposure was used as the refer-
ent group, the risk associated with cancer inci-
dence and EPTC intensity-weighted exposure
days remained elevated at the highest tertile of
EPTC exposure for all cancer (RR = 1.19;
95% CI, 0.95–1.49), colon cancer (RR = 2.59;
95% CI, 1.13–5.97), and leukemia (RR = 3.93;
95% CI, 0.87–17.67). 
We also divided the upper tertile of expo-
sure at its median to expand examination of
the association between high EPTC exposure
and cancer incidence for those cancer sites that
had ﬁve or more cases within each of the upper
two exposure levels. An increase in risk associ-
ated with the highest level of EPTC lifetime
exposure days (≥ 110) was observed when the
no-exposure group was used as the referent for
all cancer (RR = 1.30; 95% CI, 1.03–1.63)
and colon cancer (RR = 3.55; 95% CI,
1.97–6.42). The linear trend tests for all cancer
(p-trend = 0.01) and colon cancer (p-trend =
< 0.01) were also statistically signiﬁcant. When
the low-exposure group was used as the refer-
ent, only colon cancer remained signiﬁcantly
elevated (RR = 4.70; 95% CI, 2.03–10.87,
p-trend = < 0.01). An increase in risk associated
with the highest level of EPTC intensity-
weighted lifetime exposure days (≥ 333) was
observed for colon cancer when the no-
exposure (RR = 2.21; 95% CI, 1.27–3.86,
p-trend = < 0.01) and low-exposure (RR = 2.80;
95% CI, 1.13–6.94, p-trend = 0.02) referent
groups were used. The risk estimate for all can-
cer associated with the highest level of EPTC
exposure remained elevated using either the
no-exposure referent (RR = 1.14; 95% CI,
0.93–1.38, p-trend = 0.11) or the low-exposure
referent (RR = 1.15; 95% CI, 0.89–1.50,
p-trend = 0.54). However, the CI for the low-
exposure referent includes the null, and the lin-
ear trend is no longer signiﬁcant. 
We performed stratiﬁed analysis of risk for
all cancer by state of residence (Iowa vs. North
Carolina). No difference was observed in all
cancer risk when comparing the highest tertile
of EPTC exposure using either lifetime expo-
sure days or the intensity-weighted lifetime
exposure days when stratifying by state of resi-
dence. When we included all participants with
missing information in the referent group, there
was no change in the observed risk estimates for
all cancers, colon cancer, and leukemia.
Cancer incidence in a cohort of EPTC applicators
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Table 1. Enrollment characteristics [no. (%)] of men in the AHS enrolled between 1993 and 1997, by expo-
sure category to EPTC. 
No exposure Low exposurea High exposureb
Characteristic (n = 38,500) (n = 3,916) (n = 5,962)
Age (years)c
< 40 12,790 (33) 1,249 (32) 2,239 (37)
40–49 10,589 (27) 1,259 (32) 1,951 (32) 
50–59 7,891 (20) 826 (21) 1,093 (18)
≥ 60 7,230 (19) 582 (15) 679 (11)
Racec
White 37,432 (97) 3,882 (99) 5,919 (99)
Nonwhite 968 (2.5) 23 (0.6) 36 (0.6)
Missing 100 (0.3) 11 (0.5) 7 (0.5)
State
Iowa 24,152 (63) 3,577 (91) 5,471 (92)
North Carolina 14,348 (37) 339 (9) 491 (8)
Smoking
Never 20,098 (52) 2,219 (57) 3,352 (56)
Former 8,627 (22) 949 (24) 1,357 (23)
Current 8,340 (22) 679 (17) 1,133 (19)
Missing 1,435 (4) 69 (2) 120 (2)
Educationc
≤ High school 21,656 (56) 1,863 (48) 2,950 (49)
> High school 16,046 (42) 1,985 (51) 2,919 (49)
Missing 798 (2)  68 (2) 93 (2)
Alcohol consumptionc,d
No use in preceding 12 months 12,536 (33) 861 (22) 1,165 (20)
Self-reported use in preceding 12 months 25,357 (66) 3,030 (77) 4,753 (80)
Missing 607 (2) 25 (1) 44 (1)
Family history of cancerc,e
No 23,250 (60) 2,243 (57) 3,564 (60)
Yes 12,881 (33) 1,533 (39) 2,166 (36)
Missing 2,369 (6) 140 (4) 232 (4)
Applicator type
Private 35,557 (92) 3,679 (94) 4,718 (79)
Commercial 2,943 (8) 237 (6) 1,244 (21)
Currently own or work on farmd
Never 3,560 (9) 144 (4) 823 (14)
Ever 34,409 (89) 3,757 (96) 5,111 (86)
Missing  531 (1) 15 (0.4) 28 (0.5)
Field corn productiond
No 12,364 (32) 441 (11) 1,226 (21)
Yes 26,136 (68) 3,475 (89) 4,736 (80)
Person-years (total) 356,402 35,878 55,306
Follow-up (years)f 9.16 ± 1.91 9.06 ± 1.80 9.22 ± 1.80
Total lifetime days/year of pesticide applicationf 20.60 ± 28.95 17.63 ± 20.31 33.53 ± 34.25
aLow exposure, 1– 10 lifetime days. bHigh exposure, ≥ 10 lifetime days. cValuesdo not equal the total because of rounding
differences. dReported use at enrollment. eFamily history of ﬁrst-degree relative with any cancer excluding nonmalignant
skin cancers. fMean ± SD; reported frequency ranged from 0 to 200 days/year of pesticide application. p < 0.001.van Bemmel et al.
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Table 2. Rate ratios for selected cancer sites by lifetime exposure days to EPTC among male pesticide applicators in the AHS followed through December 2004. 
Lifetime exposure days Intensity-weighted lifetime exposure days
Cancer site Cases RRa 95% CI Cancer site Cases RRa 95% CI
All cancer All cancer
No exposure 1,824 1.00 Referent No exposure 1,824 1.00 Referent
1 < 9 202 1.13 0.98–1.31 1 > 47 118 0.98 0.82–1.19
10 – 49 94 0.96 0.78–1.19 48–111 116 1.27 1.05–1.54
≥ 50 174 1.28 1.09–1.50 ≥ 112 234 1.16 1.01–1.35
p-Trend* = < 0.01 p-Trend* = 0.02
p-Trend** = 0.05  p-Trend** = 0.28
Bladder Bladder
No exposure 85 1.00 Referent No exposure 85 1.00 Referent
1 < 9 8 1.02 0.48–2.14 1 > 47 3 0.57 0.18–1.83
10 – 49 5 1.16 0.47–2.90 48–111 7 1.71 0.78–3.74
≥ 50 9 1.21 0.58–2.52 ≥ 112 12 1.18 0.63–2.23
p-Trend* = 0.59 p-Trend* = 0.52
p-Trend** = 0.84 p-Trend** = 0.74
Blood Blood
No exposure 182 1.00 Referent No exposure 182 1.00 Referent
1 < 9 21 1.12 0.71–1.77 1 > 47 14 1.09 0.63–1.90
10 – 49 12 1.14 0.63–2.07 48–111 10 1.05 0.55–1.99
≥ 50 20 1.46 0.90–2.37 ≥ 112 28 1.37 0.91–2.08
p-Trend* = 0.12 p-Trend* = 0.14
p-Trend** = 0.20 p-Trend** = 0.25
Colon Colon
No exposure 140 1.00 Referent No exposure 140 1.00 Referent
1 < 9 10 0.76 0.40–1.46 1 > 47 7 0.79 0.37–1.70
10 – 49 10 1.44 0.75–2.77 48–111 4 0.61 0.22–1.64
≥ 50 19 2.09 1.26–3.47 ≥ 112 28 2.05 1.34–3.14
p-Trend* = < 0.01 p-Trend* = < 0.01
p-Trend** = 0.03 p-Trend** = 0.01
Leukemia Leukemia
No exposure 59 1.00 Referent No exposure 59 1.00 Referent
1 < 9 5 0.81 0.32–2.05 1 > 47 2 0.48 0.12–1.96
10 – 49 3 0.89 0.28–2.87 48–111 3 0.97 0.30–3.12
≥ 50 10 2.36 1.16–4.84 ≥ 112 12 1.87 0.97–3.59
p-Trend* = 0.02 p-Trend* = 0.05
p-Trend** = 0.04 p-Trend** = 0.05
Lung Lung
No exposure 181 1.00 Referent No exposure 244 1.00 Referent
1 < 9 17 1.31 0.79–2.19 1 > 47 10 1.10 0.55–2.17
10 – 49 3 0.44 0.14–1.37 48–111 11 1.46 0.76–2.80
≥ 50 12 1.02 0.55–1.89 ≥ 112 16 0.78 0.44–1.41
p-Trend* = 0.92 p-Trend* = 0.45
p-Trend** = 0.92 p-Trend** = 0.36
Melanoma Melanoma
No exposure 70 1.00 Referent No exposure 70 1.00 Referent
1 < 9 6 0.81 0.35–1.88 1 > 47 5 0.98 0.39–2.45
10 – 49 11 2.53 1.32–4.87 48–111 5 1.27 0.51–3.18
≥ 50 5 0.79 0.31–2.02 ≥ 112 12 1.35 0.71–2.55
p-Trend* = 0.89 p-Trend* = 0.35
p-Trend** = 0.81 p-Trend** = 0.35
Non-Hodgkin lymphoma Non-Hodgkin lymphoma
No exposure 83 1.00 Referent No exposure 83 1.00 Referent
1 < 9 10 1.16 0.59–2.26 1 > 47 8 1.36 0.65–2.84
10 – 49 7 1.45 0.66–3.18 48–111 4 0.90 0.33–2.48
≥ 50 5 0.79 0.31–2.01 ≥ 112 10 1.07 0.55–2.12
p-Trend* = 0.72 p-Trend* = 0.89
p-Trend** = 0.62 p-Trend** = 0.97
Prostate Prostate
No exposure 733 1.00 Referent No exposure 733 1.00 Referent
1 < 9 97 1.31 1.06–1.63 1 > 47 51 1.02 0.77–1.36
10 – 49 36 0.91 0.65–1.27 48–111 60 1.61 1.24–2.11
≥ 50 61 1.17 0.89–1.53 ≥ 112 82 1.05 0.83–1.33
p-Trend* = 0.31 p-Trend* = 0.55
p-Trend* = 0.62 p-Trend** = 0.24
Rectum Rectum
No exposure 73 1.00 Referent No exposure 73 1.00 Referent
1 < 9 6 0.78 0.34–1.80 1 > 47 4 0.78 0.28–2.15
10–49 2 0.46 0.11–1.90 48–111 2 0.50 0.12–2.07
≥ 50 6 1.0 0.42–2.40 ≥ 112 8 0.90 0.43–1.92
p-Trend* = 0.91 p-Trend* = 0.78
p-Trend** = 0.36 p-Trend** = 0.43
aAdjusted for age (< 40, 40–49, 50–59, ≥ 60 years), race, smoking (never, pack-years among former smokers, pack-years among current smokers), alcohol use (ever in the last 12 months),
applicator type (commercial or private), family history of cancer, state of residence, and total days pesticide use. *Trend using the no-exposure group as the referent. **Trend using the
low-exposure group as the referent. Finally, we modeled cancer risk with pesti-
cides previously reported to be associated with
colon cancer risk and those found to be most
correlated with EPTC use within the AHS
cohort. When the ﬁve most highly correlated
pesticides were added to the lifetime exposure
days model as covariates (butylate, triﬂuralin,
imazethapyr, metribuzin, and dicamba), no
signiﬁcant change was observed in our cancer
risk estimates for all cancer, colon cancer, and
leukemia. Other work from the AHS reported
an increased risk of colon cancer associated
with increasing exposure to aldicarb (Lee et al.
2007) and dicamba (Samanic et al. 2006). To
determine that our observed risk estimates
were not related to these pesticide exposures,
we modeled colon cancer risk including both
as covariates in our lifetime exposure days
model. Similarly, our risk estimate was not
markedly changed for colon cancer. 
Discussion 
In this study we evaluated lifetime EPTC
exposure as a risk factor for developing cancer.
We observed a positive association between
EPTC exposure and both colon cancer and
leukemia. Colon cancer was signiﬁcantly asso-
ciated with EPTC exposure for both lifetime
exposure days and intensity-weighted exposure
days. Leukemia was significantly associated
with lifetime exposure days to EPTC and only
marginally associated with intensity-weighted
lifetime exposure days. Other site-specific
analyses (including rectal cancer) were not
statistically signiﬁcant. 
Farmers have lower rates of cancer inci-
dence compared with the general population—
a phenomenon attributed primarily to lower
smoking rates and other lifestyle factors
(Alavanja et al. 2005; Blair and Zahm 1991).
Despite this, multiple epidemiologic studies
have reported links between pesticide use and
several different types of cancer, including
colon cancer. A case study of farmers in Italy
found a marginal association between colon
cancer risk and pesticide use among orchard
farmers (Forastiere et al. 1993). Cohort studies
within the United States have reported an asso-
ciation between colorectal cancer rates and
occupational exposure to the herbicide alachlor
(Acquavella et al. 1996, 2004), although these
observation were based on a relatively small
number of cases. Within the AHS cohort,
aldicarb (Lee et al. 2007) and dicamba
(Samanic et al. 2006) have been associated
with an increased risk of colon cancer. 
A few studies from the AHS cohort have
reported no signiﬁcant change in colon cancer
risk with pesticide use (Alavanja et al. 2003;
Beane Freeman et al. 2005; Lee et al. 2007).
Recent work by Lee et al. (2007) evaluated
the association between ever/never use of 50
different pesticides (including EPTC) and
colon cancer. Similar to our study, this report
did not ﬁnd a signiﬁcant association between
ever/never use of EPTC and colon cancer risk
[our data: RR = 1.35; 95% CI, 0.93–1.97;
Lee et al. (2007) data: odds ratio = 1.2; 95%
CI, 0.8–1.8]. Unlike our evaluation, this
group did not expand their analysis to quan-
tify an exposure response to EPTC lifetime
exposure because it did not fit their criteria
for extended analysis. Other studies report a
decreased relative risk of colon cancer
observed among organochlorine (Purdue
et al. 2006) and dichlorophenoxyacetic acid
(Lee et al. 2007) applicators in the AHS,
although no clear dose–response relationship
between increasing pesticide exposure days
and colon cancer incidence was observed. 
We looked at a number of other factors
known to be associated with an increased risk
for colon cancer. A family history of colon
cancer among first-degree relatives, smoking
status, body mass index, and increasing age
were all statistically associated with an
increased risk of colon cancer among EPTC
applicators, but these potential confounders
did not alter the observed increase in risk.
Similar results were obtained for all cancer
and leukemia. 
Some epidemiologic studies suggest that
leukemia and other immunologically related
cancers may be related to pesticide exposure.
Organophosphate exposure has been associ-
ated with an increased risk of developing non-
Hodgkin lymphoma (Cantor et al. 1992;
De Roos et al. 2003; Waddell et al. 2001)
and leukemia (Beane Freeman et al. 2005;
Brown et al. 1990). The carcinogenic effects
resulting from organophosphate exposure are
hypothesized to be related to altered immune
activity by irreversibly inhibiting acetylcholine
esterase (Kawashima and Fujii 2003). EPTC
is a reversible cholinesterase inhibitor that can
also lead to neurotoxicity (Smulders et al.
2003, 2004; U.S. EPA 1999). Cholinesterases
catalyze the hydrolysis of the acetylcholine
into choline and acetic acid during neuro-
transmission. Although the mechanism of
inactivation is slightly different, it is plausible
that prolonged exposure to thiocarbamates
like EPTC may induce a immunogenic effect
similar to that observed with the organophos-
phates by disrupting similar biologic meta-
bolic pathways. Experimental studies are
needed to substantiate this hypothesis. 
Although the AHS is a large cohort with
comprehensive exposure assessments, one limi-
tation to this study is the relatively small num-
ber of exposed incident cases for certain cancers.
These small numbers resulted in unstable risk
estimates and limited interpretability of the
association between cancer incidence and
EPTC exposure. There is also the potential for
exposure misclassiﬁcation because many partici-
pants were reporting past and present pesticide
exposure. Because the exposure classiﬁcations
were made before disease diagnosis, any mis-
classification should be nondifferential and
result in an attenuation of observed risk esti-
mates. Although exposure misclassiﬁcation may
exist within our study, evaluation of this issue
within the AHS cohort has shown that report-
ing of pesticide use is similar to other variables
described by participants, including diet and
alcohol consumption (Blair et al. 2002; Hoppin
et al. 2002). Additionally, the exposure scores
have been shown to provide a reasonably valid
measure of exposure intensity by comparing
urine metabolite concentrations with pesticide
exposure algorithm results among applicators
applying the herbicides 2,4-dichlorophenoxy-
acetic acid (2,4-D) (r = 0.34, p = 0.03) and
4-chloro-2-methylphenoxyacetic acid (MCPA)
(r = 0.18, p = 0.05) (Coble et al. 2005).
Another evaluation of the algorithm scores
found similar correlations with urinary metabo-
lites for liquid applications of the herbicides
glyphosate (r = 0.23, 95% CI, –0.07, 0.48),
2,4-D (r = 0.25, 95% CI, 0.10–0.54), and liq-
uid applications of the insecticide chlorpyrifos,
(r = 0.42, 95% CI, 0.01–0.70), but not for
granular applications (r = –0.44, 95% CI,
–0.83 to 0.29) (Acquavella et al. 2006).
However, the geometric mean of 3,5,6-
trichloro-2-pyridinol (TCPy) (the primary
metabolite of chlorpyrifos) concentration in the
urine was much lower after granular (10 ppb)
compared with liquid (24 ppb) applications of
chlorpyrifos. The AHS enrollment question-
naire did not collect information on the fre-
quency with which EPTC was applied as a
granular versus liquid formulation. However,
among the 46% of EPTC applicators who
completed a more detailed take-home question-
naire, 92% reported using a broadcast method
to apply herbicides, whereas 37% reported
using an in-furrow method. Granular formula-
tions are usually applied using an in-furrow
method, whereas liquid application methods
are more often applied using a broadcast
method. Another limitation to note is that
EPTC was ﬁrst licensed for use in the United
States in 1958 (U.S. EPA 1999) and has since
been manufactured by a number of companies;
therefore, its exact composition as an applied
pesticide product may have changed over time
and varied among pesticide manufactures.
Exposure metrics that account for only dura-
tion and intensity do not address possible tem-
poral variability in EPTC product composition.
Pesticide applicators are exposed to a number of
different chemicals in addition to EPTC. We
tried to minimize this potential confounding,
adjusting for the possible effects by including
total lifetime days of all pesticide use in our
model. However, it is plausible that some con-
founding remained, biasing our risk estimates.
Finally, without a strong a priori hypothesis to
focus our analysis on any one cancer site, we
chose to look at multiple cancer sites. This is
Cancer incidence in a cohort of EPTC applicators
Environmental Health Perspectives • VOLUME 116 | NUMBER 11 | November 2008 1545one of the ﬁrst epidemiologic studies to com-
prehensively evaluate the potential association
between EPTC exposure and cancer. Given
the paucity of available data, we believe it is
appropriate to evaluate all cancer sites and to
report the results for all cancer sites that we
analyzed. Further follow-up is clearly necessary,
both in this cohort and in other studies to clar-
ify the patterns of association we observed in
this study. 
The central strength of this study is its
prospective design, allowing for deﬁnitive assess-
ments of temporality between pesticide exposure
and disease incidence. In addition, detailed
information on exposure to EPTC (and other
pesticides) was available including information
on exposure to 22 different pesticides, the num-
ber of days applied per year, use of personal pro-
tective equipment, and application method.
These factors were components of the different
exposure metrics used in this study. Cancer inci-
dence was identiﬁed through population-based
registries, minimizing the potential for ascertain-
ment bias and information bias. Finally, our
study allowed us to analyze one speciﬁc pesticide
while adjusting for lifetime use of other pesti-
cides and lifestyle variables—points that have
not been addressed in previous cohort studies of
occupationally exposed workers. 
The U.S. EPA (1999) currently reports that
EPTC is likely not a human carcinogen based
on short- and long-term laboratory studies, yet
the previous epidemiologic data on EPTC
exposure and cancer risk were limited. This is,
to our knowledge, the largest epidemiologic
examination of EPTC exposure and cancer risk
conducted to date. We provide evidence of an
association between the highest category of life-
time EPTC exposure days and cancer risk,
specifically for leukemia and colon cancer.
However, the evidence for colon cancer is more
indicative of a stronger association with EPTC
exposure than that presented for leukemia. The
small number of leukemia cases (n = 18, with
the median exposure category having only three
cases) among individuals exposed to EPTC lim-
ited our ability to interpret the association. As
more cancers are diagnosed and the cohort ages,
analyses that further explore the potential asso-
ciation between EPTC exposure and cancer
incidence should be performed to assess the
reproducibility of our observations.
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